Glaucoma is one of the leading causes of irreversible blindness, and lowering intraocular pressure alone is insufficient to rescue lost retinal ganglion cells (RGCs) or restore visual function. In this study, we intravitreally injected a liquid chitosan gel loaded with nerve growth factor (NGF), previously developed by our group, into the vitreous body of rats with ocular hypertension-induced glaucoma. Using a combination of techniques--including multiplex immunofluorescence staining, TUNEL staining, CTB tracing, Western blotting, visual electrophysiology, and behavioral assessments--we demonstrated that, compared with the lesion control (LC) group, the NGF-chitosan hydrogel significantly enhanced RGC survival following glaucomatous injury (by approximately 27%), preserved dendritic architecture and long-distance axonal projections, and promoted recovery of visual function. Mechanistically, treatment with the NGF-chitosan hydrogel upregulated the expression of NGF and its high-affinity receptor, tropomyosin receptor kinase A (TrkA), in the retina. In addition, it suppressed retinal glial activation and enhanced mammalian target of rapamycin (mTOR) signaling, collectively contributing to RGC protection and repair. Notably, we further observed activation of Nestin+ neural stem cells in the ciliary body region, along with their differentiation into BrdU+/Brn3a+ neuron-like cells; the precise mechanisms underlying this phenomenon warrant further investigation. In conclusion, intravitreal delivery of NGF-chitosan hydrogel provides novel mechanistic insights and represents a promising therapeutic strategy for the treatment of glaucoma.
N-methyl-D-aspartate (NMDA) excitotoxicity drives mitochondrial dysfunction and retinal ganglion cell (RGC) loss in blinding retinal disorders. Ciliary neurotrophic factor (CNTF) is neuroprotective, but its short half-life limits long-term therapy. Here, we investigated whether mitochondrial homeostasis mediates the sustained protection of a CNTF-loaded chitosan hydrogel. In vitro, free CNTF and the hydrogel equally protected RGCs against NMDA, effects completely abolished by the mitochondrial uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP). In vivo, free CNTF provided only transient rescue, whereas the hydrogel sustained RGC survival, mitochondrial integrity, and visual function for 28 days, with persistent upregulation of mitochondrial biogenesis genes. Adeno-associated virus-mediated DRP1 overexpression-induced mitochondrial fission fully reversed the hydrogel’s benefits, mirroring CCCP inhibition. Collectively, intact mitochondrial homeostasis is essential for the long-term neuroprotection of the CNTF-chitosan hydrogel, which extends CNTF retention without altering its mitochondrial-dependent mechanism. This hydrogel represents a promising long-acting treatment for retinal excitotoxicity.
Purpose: Chromosome 3 loss is an independent risk factor for uveal melanoma (UM), but its exact molecular mechanisms remain unclear. This study was designed to investigate the relationship between chromosome 3 loss and molecular alterations at multiple levels to construct a prognostic model. Methods: Forty-four UM cases with chromosome 3 loss (chr3 del group) and 36 UM cases without copy number variation on chromosome 3 (chr3 wt group) were collected from the Cancer Genome Atlas (TCGA). The TCGA dataset was subjected to a univariate Cox regression analysis to identify different expressed genes, and a subsequent random forest algorithm analysis revealed significant changes in different expressed genes, which were used to develop key biomarkers for UM. Following that, the immune cell infiltration analysis and drug sensitivity analyses were carried out. The UM cell line was then utilized to investigate the potential functions of the key biomarker via cell apoptosis, proliferation, cycle assays, WB, and RT-qPCR. Results: By analyzing the 80 cases data in TCGA, the authors unveiled molecular changes relevant to loss of chromosome 3 in UM as well as their poor survival. In addition, machine learning analysis identified three hub genes (GRIN2A, ACAN, and MMP9) as potential therapeutic targets. The differentially enriched pathways between the two groups were mainly about immune-system activity, and hub genes expression was also highly correlated with immune infiltration levels. Conclusion: Chromosome 3 loss has considerable clinical significance for UM, and GRIN2A may be useful in diagnosing, treating, and prognosticating the condition.